TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Setup error values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot Posture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With CMV Viremia Clearance as Defined by Site Investigator at the Index Episode and for Recurrent Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With Organ Rejection From SOT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants who Died due to CMV Infection From SOT and Index Date
Endpoint domain: Mortality/survival
Primary endpoint: Assessment of steatosis and fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Completion of clinical genetic testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of People Completely Viewing the Decision Support Tool
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Missed Visit Proportion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: pallidopeduncular and pedunculopallidal pathway activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GPe activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Rating Scales
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Temperature profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PTSD score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Length and adherence of probiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of CD8+, CD4+, and T-reg cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Myofiber cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Assessment of myofibrillar protein synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in maximal isometric muscle strength and superimposed twitch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Heart Rate Response to Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Biodistribution of [99mTc]Duramycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dosimetry evaluation of [99mTc]Duramycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity for detecting AF with PPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Algorithm concordance index or c-index for predicting AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Dose Limiting Toxicities (DLTs) With Siremadlin Monotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Dose Limiting Toxicity (DLT) With Siremadlin in Combination With Donor Lymphocyte Infusion (DLI)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Are Alive and Maintained Complete Remission (CR) or Complete Response With Incomplete Hematological Recovery (CRi)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Psychometric Hepatic Encephalopathy Score (PHES)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: University of California Los Angeles (UCLA) Loneliness Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Adolescent Longitudinal Interval Follow-up Evaluation (A-LIFE) Psychiatric Status Ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Children's Affective Lability Scale (CALS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Conflict Behavior Questionnaire (CBQ) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Kiddo-KINDL Quality of Life Questionnaire for Children
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Carnitine Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Choline Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Cholesterol Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL Cholesterol Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HDL Cholesterol Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: toxicity from treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients screened who consent
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients screened who meet eligibility criteria
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to PERT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eczema Area and Severity Index (EASI) score <= 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Investigator's Global Assessment (IGA) × Body Surface Area (BSA) score <= 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of clinically significant abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Columbia-Suicide Severity Rating Scale (C-SSRS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Muscle Recruitment Maximum Strength (RMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Asymmetries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Verticality Perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of needle depth prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Wong-Baker Facial Expression Evaluation Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adverse events and Serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in wrist velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Stimulus Response Curve parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monitoring for incidence of Adverse Events (AEs)/Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Neurophysiology of Pain Questionnaire (NPQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Clinical Assessment Vignette (CAV)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Health care Pain Attitudes and Impairment Relationship Scale (HC-PAIRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Management Advice Vignette (MAV)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Gut Microbial Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Microbial Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and nature of injection site reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and nature of systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and nature of Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Tachyarrhythmia-related death
Endpoint domain: Mortality/survival
Primary endpoint: Externally resuscitated cardiac arrest
Endpoint domain: Mortality/survival
Primary endpoint: Oxytocin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Constipation severity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quality of Life change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bristol stool form score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Concentration of risankizumab in breastmilk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cmax of midazolam, s-warfarin, omeprazole, Repaglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of midazolam, s-warfarin, omeprazole, Repaglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf of midazolam, s-warfarin, omeprazole, Repaglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell count of CAR NK-CD19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of CAR NK-CD19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of CAR NK-CD19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conditional Weight Gain Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Device Deficiencies
Endpoint domain: Adverse events/effects
Primary endpoint: GMT and GMI of specific IgG total antibodies against variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time of first analgesia requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LAG-3 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: immune checkpoint protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of recompensation in pediatric subjects with decompensated cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of true positive results of FNAC after thyroidectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of malignant thyroid nodules not observed by FNAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence rate of hand eczema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Menopause Symptoms Evaluation Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Arterial calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mental health literacy scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oral morphine equivalent (OME)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occlusion Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: World Health Organization Disability Assessment Schedule (WHODAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Generalized Anxiety Disorder Screener (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-traumatic stress disorder Checklist-Civilian Version (PTSD CL)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient adherence to culprit medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time spent on the labor and delivery unit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in 5 times sit-to-stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of Hemoglobin A1c levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Lipid Profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Physical Activity Level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Weight from Baseline to 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Weight from Baseline to 30 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Integrated Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Area of contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Score on PROMIS - Pain Interference
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time between voids during conditional SNM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Detrusor contraction period during conditional SNM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Voided urine volume during conditional SNM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of AdMSC-associated adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Conversion resection rate of liver metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in severity of SBD (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Umbilical ischaemic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in headache-related disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complete Response (CR) Rate at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to diagnosis and/or treatment of cardiac arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of participants maintaining clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with safety events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with safety events leading to a change of treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with safety events with outcome of death
Endpoint domain: Mortality/survival
Primary endpoint: Meaning made of stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-efficacy to avoid suicidal action
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Bone marrow cellularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet maintenance response time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Circulating Cathepsin B (CTSB) Myokine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attentional Inhibition Accuracy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attentional Inhibition Reaction Time
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Unplanned cessation of care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Participant Rating of Application Feasibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Spike SARS-COV-2 protein in placental tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of words read without assistive technology before training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of misread without assistive technology before training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to read without assistive technology before training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Outcomes in patients with parenchymal and extraparenchymal neurocysticercosis - 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: IVIG resistance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Monthly eligibility and recruitment rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient-reported outcome completion rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient empowerment and self-efficacy measured by CASE-Cancer
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety related impairment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression related impairment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pharmacokinetic properties of BV100
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of oral midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Curve (AUC) of oral midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Tested Positive for IgG Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from full epistaxis to cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Family networks
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Adherence to study activities
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant Satisfaction with the program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Longer-term unmet needs after stroke
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Stroke impact
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in frequency of phlebotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quality of life SGRQ at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: The annual rate of pulmonary exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Quality of life questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: recommend phase 2 dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Brief esophageal dysphagia questionnaire (BEDQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Eckardt Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with retained barium column ≥5cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of stent strut coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Survival rate of the patients
Endpoint domain: Mortality/survival
Primary endpoint: Viral Load Log10 Change from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days alive, ventilator-free and kidney replacement therapy (KRT)-free
Endpoint domain: Mortality/survival
Primary endpoint: Maternal reported infant wakings
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Retention to PrEP follow up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Healthcare burden
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Parietal cortex activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Local Dynamic Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Turn duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Turn jerk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of the sleep intervention
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Satisfaction with the sleep intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the occurrence of colorectal neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to first occurrence of upper GI clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of cognitive function score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Delivery within 28 days
Endpoint domain: Mortality/survival